CVRx, Inc. CVRX 深 滬
已收盤 02-06 16:00:00 美东时间
6.55
-0.090
-1.36%
華盛通- 最 高6.8199
- 今 開6.69
- 成交量 22.49万股
- 最 低 6.44
- 昨 收 6.64
- 總市值 1.72亿
- 52周最高 15.36
- 市盈率 靜 --
- 換手率 0.86%
- 52周最低 4.2993
- 委 比 67.05%
- 總股本 2621.01万
- 歷史最高 33.135
- 量 比 0.73
- 振 幅 5.72%
- 歷史最低 4.2993
- 每 手 1
- 風險率 2.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CVRx Launches BENEFIT-HF Trial To Evaluate Barostim In Expanded Heart Failure Population
CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced initiation of
01-23 05:38
CVRx Sees FY2026 Sales $805.000M vs $64.861M Est
CVRx (NASDAQ:CVRX) sees FY2026 sales of $805.000 million vs $64.861 million analyst estimate.
01-12 21:25
CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy
CVRx announced that its Barostim therapy for heart failure patients now uses Category I CPT codes, replacing the Category III codes effective Jan. 1, 2026. The new codes, accessible on CVRx’s website, aim to simplify reimbursement processes nationwide and validate the therapy’s role in heart failure treatment.
01-06 13:30
CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference
CVRx, Inc. announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026. The presentation will begin at 3:45 p.m. PT and will be available via live webcast on ir.cvrx.com. CVRx is a medical device company specializing in innovative neuromodulation solutions for cardiovascular diseases. Its Barostim device, FDA-approved for heart failure patients, uses electrical pulses t...
2025-12-22 13:30
CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference
CVRx, Inc. announced that its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Dec. 3, 2025. The discussion will be webcast live at 2:00 p.m. ET via ir.cvrx.com. CVRx is a medical device company focused on innovative neuromodulation solutions for cardiovascular diseases, including its FDA-approved Barostim™ for heart failure. Investors and media can contact the company through provided ...
2025-11-19 13:30
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
Cantor Fitzgerald Maintains Overweight on CVRx, Raises Price Target to $13
Cantor Fitzgerald analyst Ross Osborn maintains CVRx (NASDAQ:CVRX) with a Overweight and raises the price target from $11 to $13.
2025-11-06 22:30
CVRx Reports Third Quarter 2025 Financial and Operating Results
CVRx公司2025年第三季度营收为1470万美元，同比增长10%，其中美国市场贡献1350万美元，活跃植入中心增加至250个。毛利率提升至87%，但净亏损1290万美元。公司更新全年营收指引至5560-5660万美元，毛利率85%-86%，运营费用9800-9900万美元。
2025-11-05 21:05
CVRx to Present at the Jefferies Global Healthcare Conference in London
CVRx, Inc. announced that its management team will present at the Jefferies Global Healthcare Conference in London on Nov. 18, 2025. The presentation will be available via webcast at 8:00 a.m. GMT / 4:00 a.m. ET. The live audio webcast can be accessed at ir.cvrx.com.The company specializes in developing neuromodulation solutions for cardiovascular diseases. Its product, Barostim™, is the first FDA-approved technology using neuromodulation to impr...
2025-11-04 13:30
CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025
CVRx, Inc. (NASDAQ: CVRX), a medical device company specializing in neuromodulation solutions for cardiovascular diseases, announced it will release its third quarter 2025 financial and operating results after market close on November 5, 2025. A conference call to discuss the results will be held at 4:30 p.m. Eastern Time that day, with a live webcast available on the company’s investor relations website. CVRx develops innovative therapies like B...
2025-10-22 20:30
